Viridian Therapeutics to Present Preclinical Data on VRDN-001 and VRDN-002 at the 90th Annual Meeting of the American Thyroid Association
Viridian Therapeutics (NASDAQ: VRDN) has announced the presentation of two posters featuring preclinical data on its drug candidates, VRDN-001 and VRDN-002, at the 90th Annual Meeting of the American Thyroid Association from September 30 to October 3, 2021.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Viridian Therapeutics (NASDAQ: VRDN) has announced the presentation of two posters featuring preclinical data on its drug candidates, VRDN-001 and VRDN-002, at the 90th Annual Meeting of the American Thyroid Association from September 30 to October 3, 2021. The posters focus on VRDN-002's pharmacokinetic profile and clinical promise as a second-generation IGF-1R antagonist for Thyroid Eye Disease, and the characterization of VRDN-001 as a potent anti-IGF-1R inhibitory antibody. These developments signal ongoing advancements in treatment options for patients with thyroid eye disease.
Positive
- Presentation of preclinical data for VRDN-001 and VRDN-002 at a prominent conference, indicating active research and development.
- Demonstrated clinical promise of VRDN-002, which may enhance future treatment options for Thyroid Eye Disease.
Negative
- None.
Details
News Market Reaction – VRDN
The recorded move for VRDN in the trading session of this news was -3.24%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
WALTHAM, Mass., Sept. 30, 2021 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company advancing new treatments for patients suffering from serious diseases but underserved by today's therapies, announced today that two posters featuring preclinical data on VRDN-001 and VRDN-002 are scheduled to be presented at the 90th Annual Meeting of the American Thyroid Association (ATA), which is being held from September 30th through October 3rd.
| Poster Presentation Details: | |
| Title: | VRDN-002, A Second-Generation Insulin Like Growth Factor-1 Receptor (IGF-1R) Antagonist Antibody for Thyroid Eye Disease: Preclinical Pharmacokinetic Profile and Clinical Promise |
| Poster: | #37 |
| Poster Session (1): | Thursday Poster Review Session |
| Time and Date: | Thursday, September 30, 2021, 12:15-1:00 p.m. EDT (Virtual Poster) |
| Poster Session (2): | Thursday Highlighted Posters Session #3 |
| Time and Date: | Thursday, September 30, 2021, 4:00-5:00 p.m. EDT |
| Title: | Characterization of VRDN-001, a High Affinity and Potent anti-IGF-1R Inhibitory Antibody in Development for the Treatment of Thyroid Eye Disease |
| Poster #: | #187 |
| Poster Session: | Saturday Poster Review Session |
| Time and Date: | Saturday, October 2, 2021, 1:00-2:00 p.m. EDT |
About Viridian Therapeutics, Inc.
Viridian Therapeutics is a biotechnology company advancing new treatments for patients suffering from serious diseases but underserved by today’s therapies. Viridian’s most advanced program, VRDN-001, is a differentiated monoclonal antibody targeting insulin-like growth factor-1 receptor (IGF-1R), a clinically and commercially validated target for the treatment of thyroid eye disease (TED), a debilitating auto-immune disease that causes inflammation and fibrosis within the orbit of the eye which can cause double vision, pain, and potential blindness. Patients with severe disease often require multiple remedial surgeries to the orbit, eye muscles and eyelids. Viridian is based in Waltham, Massachusetts.
Viridian Contacts:
Investors:
Dan Ferry
LifeSci Advisors
617-430-7576
IR@viridiantherapeutics.com
Media:
Darby Pearson
Verge Scientific Communications
703-587-0831
PR@viridiantherapeutics.com
Source: Viridian Therapeutics, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.